Download NGC Search Results

Ca del colon-retto
NGC Browse - Disease/Condition Results
Diseases (MeSH Category) - List all 1098 guidelines
Neoplasms - List all 213 guidelines
Neoplasms by Site - List all 176 guidelines
Digestive System Neoplasms - List all 48 guidelines
Gastrointestinal Neoplasms - List all 35 guidelines
Intestinal Neoplasms - List all 32 guidelines
Colorectal Neoplasms - List all 32 guidelines
1. 2000 update of recommendations for the use of tumor markers in breast and colorectal
cancer: clinical practice guidelines of the American Society of Clinical Oncology.
American Society of Clinical Oncology - Medical Specialty Society. 1997 (revised 2001
Mar). 14 pages.
2. ACR Appropriateness Criteria™ for pre-treatment staging of colorectal cancer. American
College of Radiology - Medical Specialty Society. 1996 (revised 1999). 8 pages.
3. Management of colorectal cancer. A national clinical guideline. Scottish Intercollegiate
Guidelines Network - National Government Agency [Non-U.S.]. 2003 Mar. 47 pages
4. Preventive health care, 2001 update: colorectal cancer screening. Canadian Task Force on
Preventive Health Care - National Government Agency [Non-U.S.]. 2001. 2 pages.
5. Use of irinotecan (Camptosar®, CPT-11) combined with 5-fluorouracil and leucovorin
(5FU/LV) as first-line therapy for metastatic colorectal cancer. Practice Guidelines
Initiative - State/Local Government Agency [Non-U.S.]. 2001 Oct 23 (updated online 2003
Feb). 20 pages.
6. Use of irinotecan in the treatment of metastatic colorectal carcinoma. Practice Guidelines
Initiative - State/Local Government Agency [Non-U.S.]. 1999 Apr 30 (updated online 2000
Apr).
7. Use of raltitrexed (Tomudex) in the management of metastatic colorectal carcinoma.
Practice Guidelines Initiative - State/Local Government Agency [Non-U.S.]. 1998 May 22
(updated online 2003 Feb).
AHRQ Search Results: 1
U.S. Preventive Services Task Force. Colorectal Cancer - Screening July 2002
PNLG Search Results: 0
CMA Search Results: 4
1. Use of irinotecan (Camptosar®, CPT-11) combined with 5-fluorouracil and leucovorin
(5FU/LV) as first-line therapy for metastatic colorectal cancer. Practice Guidelines
Initiative - State/Local Government Agency [Non-U.S.]. 2001 Oct 23 (updated online 2003
Feb). 20 pages.
2. Use of irinotecan in the treatment of metastatic colorectal carcinoma. Practice Guidelines
Initiative - State/Local Government Agency [Non-U.S.]. 1999 Apr 30 (updated online 2000
Apr).
3. Use of raltitrexed (Tomudex) in the management of metastatic colorectal carcinoma.
Practice Guidelines Initiative - State/Local Government Agency [Non-U.S.]. 1998 May 22
(updated online 2003 Feb).
4. Preventive health care, 2001 update: colorectal cancer screening. Canadian Task Force on
Preventive Health Care - National Government Agency [Non-U.S.]. 2001. 2 pages.
NeLH Search Results: 5 record
1. NICE 2000. Guidance on the use of Laparoscopic Surgery for Colorectal Cancer
2. NICE 2002. Guidance on the use of irinotecan, oxaliplatin & raltitrexed for the treatment of
advanced colorectal cancer
3. SIGN. Management of Colorectal Cancer
4. NICE 2003. Guidance on the use of capecitabine and tegafur with uracil for metastatic
colorectal cancer
5. 2002 British gastroenterology society. Colorectal Cancer Screening : Guidelines for follow
up after resection of colorectal cancer
SIGN search: 1
SIGN. Management of Colorectal Cancer
New Zealand Search Results: 0
Cochrane search: 3 records
1. Screening for colorectal cancer using the faecal occult blood test, Hemoccult (Cochrane
Review)
2. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane
Review)
3. Palliative chemotherapy for advanced or metastatic colorectal cancer (Cochrane Review)
4. Curative Surgery for Obstruction from Primary Left Colorectal Carcinoma: Primary or
Staged Resection? (Cochrane Review)
5. Stapled versus handsewn methods for colorectal anastomosis surgery (Cochrane Review)
6. Mechanical bowel preparation for elective colorectal surgery (Cochrane Review)
7. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal
cancer metastatic to the liver (Cochrane Review)
8. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery (Cochrane
Review)
CRD Databases search: 15 records
1. Cost effectiveness analysis of intensive versus conventional follow up after curative
resection for colorectal cancer. Renehan A G, O'Dwyer S T, Whynes D K. BMJ
2004;328:81.
2. Impact on survival of intensive follow up after curative resection for colorectal cancer:
systematic review and meta-analysis of randomised trials. Renehan A G, Egger M,
Saunders M P, O'Dwyer S T. BMJ 2002; 324: 813-816.
3. Should the MUHC approve the use of colorectal stents?. McGregor M. Technology
Assessment Unit of the McGill University Health Centre (MUHC) 2003: 13.
4. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal
cancer. National Institute for Clinical Excellence. National Institute for Clinical Excellence
(NICE) 2003 (Technology Appraisal Guidance - No.61): 25.
5. Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a
review (French). Selke B, Lebrun T, Comte S. Bulletin du Cancer 2003;90(2):143-149.
6. G17DT for stomach, pancreatic and colorectal cancer - horizon scanning review.
National Horizon Scanning Centre. National Horizon Scanning Centre (NHSC) 2003.
7. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment
of metastatic colorectal cancer: systematic review and economic evaluation. Ward S,
Kaltenthaler E, Cowen J, Brewer N. Health Technology Assessment Vol.7: No.32 2003:
106.
8. Health technology assessment of positron emission tomography in oncology - a
systematic review. Institute for Clinical Evaluative Sciences (ICES) 2003: 21.
9. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced
colorectal cancer. Health Technology Board for Scotland (HTBS) (merged into NHS
Quality Improvement Scotland (NHS QIS)) 2002 (Understanding HTBS Advice): 10.
10. A rapid and systematic review of the evidence for the clinical effectiveness and costeffectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced
colorectal cancer. Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M. Health
Technology Assessment 2002; 5(25): 1-128.
11. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and
folinic acid as first line treatment of metastatic colorectal cancer. Cunningham D, Falk
S, Jackson D. British Journal of Cancer 2002;86(11):1677-1683.
12. Cetuximab for head and neck and colorectal cancer. National Horizon Scanning Centre.
National Horizon Scanning Centre (NHSC) 2002 (New and Emerging Technology
Briefing): 5.
13. Costs and consequences of different chemotherapy regimens in metastatic colorectal
cancer. Hale J P, Cohen D R, Maughan T S, Stephens R J. British Journal of Cancer
2002;86(11):1684-1690.
14. Computed tomographic colonography (virtual colonoscopy). Health Technology
Advisory Committee. Health Technology Advisory Committee (HTAC) 2002.
15. Scoring systems for assessing postoperative risk in colorectal surgery. Bernath V.
Centre for Clinical Effectiveness (CCE) 2002 (Evidence Centre Evidence Report): 8.